News | Stents Peripheral | September 28, 2015

Eluvia Vascular Stent System Demonstrates 96.1 Percent 12-month Primary Patency

MAJESTIC trial data support strong safety profile with low target lesion revascularization rate

Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

September 28, 2015 — New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting vascular stent system reflect a primary patency rate of more than 96 percent. These results represent the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials. The Eluvia Stent System is an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery (SFA) or proximal popliteal artery (PPA), a result of peripheral artery disease (PAD).

Results from the MAJESTIC trial — which were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting in Lisbon, Portugal — also included a low 12-month target lesion revascularization (TLR) rate of 3.8 percent, with no observed stent fractures and no amputations. 

"Achieving a 96 percent primary patency rate at one year, with low major adverse events, is exceptional," said Prof. Stefan Muller-Hulsbeck, M.D., PhD, principal investigator and chairman, Vascular Center Diako Flensburg and head of the Department of Diagnostic and Interventional Radiology /Neuroradiology, Academic Hospitals Flensburg, Germany. "In my opinion, the sustained release of paclitaxel enabled by this technology could represent a significant advancement in the treatment of patients with peripheral arterial disease."

The MAJESTIC trial, a prospective, multicenter clinical trial, enrolled 57 patients across Europe, Australia and New Zealand, with an average lesion length of 70.8 mm. The trial included a high percentage of complex lesions, with 46 percent of lesions classified as total occlusions and 65 percent identified as severely calcified. 

Data from the MAJESTIC trial are expected to support global regulatory submissions. In addition, Boston Scientific has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a global, pivotal study of the Eluvia Stent System. The study, named the IMPERIAL trial, designed to support future regulatory submissions and patient enrollment, is expected to begin in the coming months.

The Eluvia Stent System is the first stent specifically designed for deployment in the SFA that utilizes the anti-restenotic drug paclitaxel in conjunction with a polymer. This drug and polymer combination is intended to facilitate sustained release of the drug over the period of time when restenosis is most likely to occur, preventing tissue growth that might otherwise block the stented artery. The Eluvia Stent System is built on the Innova Stent System platform, consisting of a self-expanding nitinol stent and an advanced, 6F low-profile triaxial delivery system for added support and placement accuracy.

For more information:

Related Content

Veryan Medical's BioMimics 3D Stent Receives PMA Approval
Technology | Stents Peripheral | October 05, 2018
Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System from the U.S. Food...
Intact Vascular Announces $20 Million Series C Financing
News | Stents Peripheral | April 27, 2018
April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million.
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral | July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral | July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral | April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral | March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral | March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral | December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral | December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Overlay Init